Advancing the PharmD Revolution in Nigeria

The recent induction of pioneer Doctor of Pharmacy (PharmD) graduates across leading Nigerian universities by the Pharmacy Council of Nigeria (PCN) is a defining moment in the long and necessary evolution of pharmacy practice in the country. With cohorts emerging from the University of Nigeria, Nsukka, the University of Ibadan, the University of Benin, and Gregory University, Uturu, the indication is that Nigeria is no longer on the margins of global pharmacy education reform. It is stepping deliberately into its centre.

For decades, pharmacy education in Nigeria, built around the Bachelor of Pharmacy degree, produced competent professionals who played essential roles in the production, supply, and distribution of medicines. However, the demands of modern healthcare have outgrown that model. Today’s patient presents with complex conditions, polypharmacy risks, and a healthcare environment that increasingly demands collaboration, precision, and accountability. The pharmacist can no longer remain at the periphery of care. The PharmD, therefore, is not a mere academic upgrade but a necessary repositioning of the profession.

The expanding accreditation of pharmacy faculties by the PCN further reflects a growing institutional ratification of this reality. So far, the Council has accredited more than 23 faculties for the PharmD programme, signalling that the transition is no longer experimental but systemic. By insisting on rigorous standards in curriculum design, faculty strength, and training infrastructure, the Council is setting the tone for a new professional order.

At the heart of this reform is a fundamental change in orientation. The PharmD model repositions the pharmacist within the healthcare ecosystem. It demands deeper clinical exposure, sharper diagnostic reasoning, and a sustained engagement with patient care. It also opens pathways into specialised practice, residency training, pharmacovigilance, health policy, and translational research. In doing so, it elevates the profession from a largely product-oriented discipline to one firmly rooted in patient-centred care.

Voices from both regulation and academia have rightly framed this transition as inevitable. The Registrar of PCN, Pharm. Ibrahim Babashehu Ahmed, has described the PharmD as a response to the evolving dynamics of healthcare delivery rather than a departure from foundational training or a mere status symbol. In the same vein, the Vice-Chancellor of the University of Ibadan, Prof. Kayode Adebowale, has challenged new graduates to transcend traditional roles and embrace their place as medication experts within multidisciplinary teams

There is also a broader strategic context. Across advanced health systems, clinical pharmacy has become indispensable. Countries such as the United States, United Kingdom, Canada, Australia, and Japan have long embedded pharmacists within patient care teams, with measurable gains in medication safety, treatment outcomes, and cost efficiency. Nigeria’s gradual alignment with this model is therefore both pragmatic and overdue.

However, it is essential to emphasise that the growing momentum must be matched with corresponding systemic changes. Educational reform cannot succeed in isolation. Many pharmacy faculties still face limitations in infrastructure, including access to modern laboratories, simulation centres, and structured clinical training platforms. Without sustained investment in these areas, the full benefits of the PharmD may not be realised.

Equally important is the need to create space within the healthcare system for these newly trained professionals. Expanding the role of clinical pharmacists requires clear policy direction, the establishment of residency programmes, and the integration of pharmacists into multidisciplinary care teams. Without these, there is a risk that the system will produce highly skilled graduates whose competencies are underutilised.

The issue of workforce retention also demands urgent attention. Nigeria continues to operate with a pharmacist-to-patient ratio that falls far below global recommendations. At the same time, many of its best-trained professionals are leaving for environments where their skills are better recognised and rewarded. If this trend persists, the gains of the PharmD reform may benefit other health systems more than Nigeria’s own.

For institutions yet to transition, the direction is now unmistakable. The early adopters, especially the University of Benin, have demonstrated that change is possible with commitment and regulatory alignment. What is required now is not hesitation, but resolve. Universities must invest, adapt, and innovate. Professional bodies must advocate more strongly for role expansion.

Most importantly, policymakers must recognise that strengthening pharmacy practice is not peripheral to health reform; it is central to it. The momentum is currently real and growing. What remains is the collective will to sustain it, deepen it, and ensure that its benefits are fully realised within Nigeria’s healthcare system.